^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    HRA00129-C004

    i
    Other names: HRA00129-C004, HRA00129C004, HRA00129 C004
    Company:
    Jiangsu Hengrui Pharma
    Drug class:
    Topoisomerase I inhibitor, c-MET-targeted antibody-drug conjugate
    Related drugs:
    1m
    HRA00129-C004, a Novel c-Met Antibody-Drug Conjugate (ADC), Exerts Encouraging Anti-Tumor Activities and Favorable Safety Profiles. (PubMed, Mol Cancer Ther)
    In summary, HRA00129-C004 is a superior c-Met ADC with relatively low affinity to c-Met, efficient internalization, and strong bystander effect. It is currently being investigated in a Phase I clinical trial for patients with advanced solid tumors.
    Journal
    |
    MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    MET expression
    |
    HRA00129-C004